During the past decade, The Catholic University of Korea St. Paul's Hospital conducted 39 clinical trials. In the 10-year time frame, 39 clinical trials started and 5 clinical trials were completed, i.e. on average, 12.8% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 4 clinical trials were completed. i.e. 23.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Catholic University of Korea St. Paul's Hospital" #1 sponsor was "Medy-Tox" with 9 trials, followed by "Seung-Jung Park" with 7 trials sponsored, "Boehringer Ingelheim" with 4 trials sponsored, "BeiGene" with 2 trials sponsored and "Chong Kun Dang Pharmaceutical" with 2 trials sponsored. Other sponsors include 30 different institutions and companies that sponsored additional 35 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Catholic University of Korea St. Paul's Hospital" #1 collaborator was "CardioVascular Research Foundation, Korea" with 14 trials as a collaborator, "Daiichi Sankyo Korea Co., Ltd." with 2 trials as a collaborator, "Neurim Pharmaceuticals Ltd." with 2 trials as a collaborator, "Biomedical Advanced Research and Development Authority" with 1 trials as a collaborator and "Boehringer Ingelheim" with 1 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "The Catholic University of Korea St. Paul's Hospital" are "Coronary Artery Disease" (12 trials), "Coronary Disease" (3 trials), "Atrial Fibrillation" (2 trials), "Diphtheria" (2 trials) and "Healthy" (2 trials). Many other conditions were trialed in "The Catholic University of Korea St. Paul's Hospital" in a lesser frequency.

Most popular intervention types in "The Catholic University of Korea St. Paul's Hospital" are "Drug" (36 trials), "Device" (10 trials), "Biological" (4 trials), "Behavioral" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Botox" (3 trials), "Meditoxin" (3 trials), "KI1001" (2 trials) and "Ociperlimab" (2 trials). Other intervention names were less common.

The vast majority of trials in "The Catholic University of Korea St. Paul's Hospital" are 54 trials for "All" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "The Catholic University of Korea St. Paul's Hospital". undefined are not yet recruiting, 13 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 32 completed trials in The Catholic University of Korea St. Paul's Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in The Catholic University of Korea St. Paul's Hospital, 4 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 4 trials that are defined as “Not Applicable".